Examkin

Question

Difficulty: MediumGastroenterology and Hepatology

A 55-year-old man with a history of decompensated alcohol-related cirrhosis is evaluated on hospital day 3. He initially presented to the emergency department with a temperature of 38.2°C (100.8°F), diffuse abdominal pain, and worsening lethargy. A diagnostic paracentesis performed on admission yielded ascitic fluid with a neutrophil count of 650/mm3650/\text{mm}^3. Due to a history of multiple recent hospitalizations, he was empirically started on intravenous meropenem. Today, his mental status has returned to baseline, his abdominal pain has markedly improved, and he is afebrile. Ascitic fluid cultures obtained on admission have finalized, growing *Escherichia coli*. Susceptibility testing indicates the organism is susceptible to cefotaxime, ceftriaxone, and ciprofloxacin, but resistant to trimethoprim-sulfamethoxazole. Which of the following is the most appropriate next step in the pharmacologic management of this patient?

  1. De-escalate therapy to intravenous cefotaximeAnswer
  2. B
    Maintain current therapy with intravenous meropenem
  3. C
    Add oral metronidazole to the current regimen
  4. D
    Transition to intravenous daptomycin
  5. E
    Discontinue all antibiotics and begin daily prophylactic norfloxacin

Answer

De-escalate therapy to a narrower-spectrum agent, such as intravenous cefotaxime.
The correct answer highlights the core principle of antimicrobial stewardship: de-escalation. The patient was appropriately started on empiric meropenem given his recent hospitalizations (which increases the risk for multi-drug resistant organisms). However, now that ascitic fluid cultures have isolated an *Escherichia coli* strain that is susceptible to narrower-spectrum agents (like cefotaxime or ceftriaxone), maintaining carbapenem therapy is no longer justified. De-escalating to intravenous cefotaxime effectively treats the spontaneous bacterial peritonitis while minimizing the risk of developing carbapenem resistance and antibiotic-associated complications such as *Clostridioides difficile* infection.

Step-by-Step Solution

1
Diagnose the primary condition and evaluate the patient's clinical trajectory.
The patient has spontaneous bacterial peritonitis (SBP) and is showing clinical improvement on empiric broad-spectrum antibiotics (meropenem).
Establishing the baseline response confirms that the current therapy is working, but safety and resistance profiles must now be optimized.
2
Analyze the ascitic fluid culture and susceptibility results.
The culture grew E. coli susceptible to third-generation cephalosporins (cefotaxime, ceftriaxone) and ciprofloxacin.
Culture data allows for the transition from empiric 'best-guess' therapy to definitive, pathogen-directed therapy.
3
Apply the principles of antimicrobial stewardship.
Therapy is de-escalated from a carbapenem (meropenem) to a third-generation cephalosporin (cefotaxime).
Meropenem is an ultra-broad-spectrum antibiotic reserved for highly resistant organisms. Using it when a narrower agent is proven effective promotes the development of multidrug-resistant organisms.

Key Concept

In the management of spontaneous bacterial peritonitis, once culture and sensitivity results confirm an organism is susceptible to a narrower-spectrum antibiotic, empiric broad-spectrum therapy should be de-escalated to prevent antimicrobial resistance.

Alternative Method

Intravenous ceftriaxone could also be chosen for de-escalation, as it is another third-generation cephalosporin to which the organism is susceptible and is heavily utilized for SBP.
Estimated Time:1m 15s
Rate this question

Topics

Gastroenterology and Hepatology

More questions from this topic